Literature DB >> 10604978

Cellular and in vivo electrophysiological effects of dronedarone in normal and postmyocardial infarcted rats.

F Aimond1, L Beck, P Gautier, O K Chérif, J M Davy, P Lorente, D Nisato, G Vassort.   

Abstract

We studied the effects of dronedarone (SR 33589) on the action potentials, membrane ionic currents, and arrhythmic activity in control rats and in rats after myocardial infarction, a model known to develop anomalous electrical activity. Dronedarone increased action potential duration in normal hearts. It had little effect on the action potentials that were already prolonged in the postmyocardial infarcted (PMI) rats. Particularly, dronedarone reduced the late sustained K(+) current, I(K) (or Isus) by 69%. Dronedarone induced only a tonic block of I(K). Similar relative inhibitions of I(K) by dronedarone were obtained in young, sham, and PMI rats, even if I(K) was less in sham than in young and further reduced in PMI rats. The EC(50) values were 0.78 and 0.85 microM in sham and PMI rats. Dronedarone induced a weak increase in the fast transient outward current, I(to). Time-to-peak and inactivation time constant of I(to) were decreased by dronedarone that also induced a marked slowing of I(to) recovery from inactivation. Similar effects were observed on the reduced I(to) recorded in PMI rats. Holter monitoring study in control, unthetered animals showed that dronedarone had no proarrhythmic effect. On rats, which after myocardial infarction exhibited ventricular premature beats, dronedarone significantly decreased beat occurrence during the 7-day treatment; this effect was sustained for two more weeks. Thus, dronedarone exerts antiarrhythmic effects on PMI rat heart. Its effects are attributable for the most part to the inhibition of outward K(+) currents and the increase in effective refractory period.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10604978

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

Review 1.  Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation.

Authors:  Ahmed M A Adlan; Gregory Y H Lip
Journal:  Drug Saf       Date:  2013-02       Impact factor: 5.606

Review 2.  Dronedarone.

Authors:  Sheridan M Hoy; Susan J Keam
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

3.  Acute inhibitory effect of dronedarone, a noniodinated benzofuran analogue of amiodarone, on Na+/Ca2+ exchange current in guinea pig cardiac ventricular myocytes.

Authors:  Yasuhide Watanabe; Junko Kimura
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-04-08       Impact factor: 3.000

4.  Novel electrophysiological properties of dronedarone: inhibition of human cardiac two-pore-domain potassium (K2P) channels.

Authors:  Constanze Schmidt; Felix Wiedmann; Patrick A Schweizer; Rüdiger Becker; Hugo A Katus; Dierk Thomas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-07-13       Impact factor: 3.000

5.  Dronedarone: evidence supporting its therapeutic use in the treatment of atrial fibrillation.

Authors:  Renee M Sullivan; Brian Olshansky
Journal:  Core Evid       Date:  2010-10-21

6.  Safety and efficacy of dronedarone in the treatment of atrial fibrillation/flutter.

Authors:  Gerald V Naccarelli; Deborah L Wolbrette; Vadim Levin; Soraya Samii; Javier E Banchs; Erica Penny-Peterson; Mario D Gonzalez
Journal:  Clin Med Insights Cardiol       Date:  2011-10-06

7.  Dronedarone for recurrent ventricular tachycardia: a real alternative?

Authors:  Victor Exposito; Felipe Rodriguez-Entem; Susana Gonzalez-Enriquez; Juan Jose Olalla
Journal:  Indian Pacing Electrophysiol J       Date:  2012-04-30

8.  Influence of Amiodarone and Dronedarone on the Force-Interval Dependence of Rat Myocardium.

Authors:  Dina S Kondratieva; Sergey A Afanasiev; Sergey V Popov
Journal:  Biomed Res Int       Date:  2018-08-02       Impact factor: 3.411

Review 9.  The current approach of atrial fibrillation management.

Authors:  Anish Amin; Aseel Houmsse; Abiodun Ishola; Jaret Tyler; Mahmoud Houmsse
Journal:  Avicenna J Med       Date:  2016 Jan-Mar
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.